A pill made to treat one of the deadliest cancers was already setting high expectations after its approval in August. But when used in combination with chemo, it could revolutionize treatment, new data suggests.
Clinical trials show the combination is not only stopping pancreatic cancer tumors from growing and spreading — it can eliminate them entirely.
“This is the closest to cure,” said oncologist Dr. Wungki Park, when presenting the findings. “We’ve never seen such a thing.”
Previous research on the drug, daraxonrasib (sold as Rasonque), showed incredible promise. The drug alone was shown to double survival time for pancreatic cancer, a total of 13.2 months up from 6.7 months.
Now, scientists are seeing how daraxonrasib works with chemo. In clinical trials, this combination caused a vast majority of tumors to stop growing, and some shrank so much they became undetectable.
The results are a “a massive, massive breakthrough” in the fight against the third-deadliest cancer, according to Dr. Wungki Park, an oncologist at Memorial Sloan Kettering, who presented the findings.
New findings
The study is part of a phase 1/2 clinical trial combining daraxonrasib with gemcitabine and nab-paclitaxel, two chemotherapy drugs, to treat pancreatic cancer that has metastasized, or spread to other parts of the body (stage 4).
When using both therapies, nine in 10 patients had tumors shrink or remain stable, while three in five patients saw significant tumor shrinkage or disappearance.
About 8.2% (one in 12) patients had no detectable cancer at the end of the study. More than 76% of participants survived past one year on the treatment.
Park noted the findings were significant because this study had a median follow up of 18.3 months, which is much longer than that of previous research. This means we now have a better idea of how long patients benefit from the treatment, and how long tumors stay shrunk.
“With longer follow-up and a larger patient population, we are seeing a notable combination of high response rates, including deep complete responses, and durable disease control, with median progression-free survival exceeding one year,” said Park.
He adds that this data presents “compelling rationale” to evaluate the drug as a “potential first-line treatment option” for pancreatic cancer.
Daraxonrasib and pancreatic cancer
Daraxonrasib is a tablet taken orally once a day. It works by targeting a mutated protein called KRAS, which Dr. Nicholas Hornstein, a medical oncologist at Northwell’s Lenox Hill Hospital, said acts like a “stuck accelerator” in cancer cells, telling them to keep growing when they should stop.
Pancreatic cancer is resistant to a number of treatments, including chemotherapy, radiation, targeted therapy and immunotherapy, making it notoriously difficult to treat.
Overall just 13.7% of patients survive the cancer past five years, making it the third-deadliest cancer. Alex Trebek, Patrick Swayze, Alan Rickman and Jerry Springer are just a few of the many who died within that time frame from this disease.
In April, former Sen. Ben Sasse shared about his experience on the drug to treat his stage 4 pancreatic cancer. He experienced a relatively common side effect of skin toxicity. In clinical trials, dermatologic toxicity occurred in 86% of patients treated with this drug — 10% had grade 3 or severe reactions.
“I take it orally, but it’s a nasty drug,” he said. “It causes crazy stuff like my body can’t grow skin and so I bleed all out of a whole bunch of parts of me that shouldn’t be bleeding.”
It was a tradeoff for more time. He was diagnosed with cancer in December 2025 and was given three to four months to live, which he far exceeded. In September, he revealed some tumors are now developing resistance to treatment.
“People with treatment-naïve metastatic pancreatic cancer urgently need more effective treatment options, given the limited clinical benefit of current chemotherapy regimens,” said Dr. Alan Sandler, chief development officer of Revolution Medicines, the maker of daraxonrasib.












